1. Home
  2. IIPR vs GENB Comparison

IIPR vs GENB Comparison

Compare IIPR & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innovative Industrial Properties Inc.

IIPR

Innovative Industrial Properties Inc.

HOLD

Current Price

$53.70

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$12.31

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
IIPR
GENB
Founded
2016
2018
Country
United States
United States
Employees
23
N/A
Industry
Real Estate
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IIPR
GENB
Price
$53.70
$12.31
Analyst Decision
Hold
Analyst Count
4
0
Target Price
$45.00
N/A
AVG Volume (30 Days)
294.0K
810.1K
Earning Date
01-01-0001
N/A
Dividend Yield
14.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.18
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$44.58
$11.00
52 Week High
$66.34
$13.95

Technical Indicators

Market Signals
Indicator
IIPR
GENB
Relative Strength Index (RSI) 57.86 48.72
Support Level $51.47 $11.00
Resistance Level $54.14 $13.70
Average True Range (ATR) 1.76 1.17
MACD -0.13 0.02
Stochastic Oscillator 46.44 42.54

Price Performance

Historical Comparison
IIPR
GENB

About IIPR Innovative Industrial Properties Inc.

Innovative Industrial Properties Inc is a real estate investment trust focused on the acquisition, ownership and management of specialized industrial and commercial properties in the United States. Its properties are prominently leased to state-licensed operators for their regulated cannabis facilities. The company conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by its Operating Partnership, directly or through subsidiaries. Its segments are: Cannabis Portfolio and Life Science Portfolio, with the majority of revenue coming from the Cannabis Portfolio segment, which involves acquiring, developing, and leasing real estate to regulated cannabis operators on long-term triple-net leases.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: